Cutaneous cylindroma: it's all about MYB by Corda, G & Sala, A

Journal of Pathology
J Pathol 2016; 0: 000–000
Published online in Wiley Online Library
(wileyonlinelibrary.com) DOI: 10.1002/path.4746
INVITED COMMENTARY
Cutaneous cylindroma: it’s all about MYB#
Gabriele Corda •1,2 and Arturo Sala1,2,*AQ1
1 College of Health and Life Sciences, Brunel University, London, UK
2 Institute of Environment, Health and Societies, Brunel University, London, UK
*Correspondence to: A Sala, Institute of Environment, Health and Societies, College of Health and Life Sciences, Heinz Wolff Building, Brunel
University, London UB8 3PH, UK. E-mail: arturo.sala@brunel.ac.uk
#Invited commentary for Rajan N, Andersson MK, Sinclair N, et al. Overexpression of MYB drives proliferation of CYLD-defective cylindroma
cells. J Pathol 2016; 239: 197–205.
Abstract
Cutaneous cylindroma is a rare benign tumour that occasionally turns into malignant cylindrocarcinoma. The
AQ2
cancer can be sporadic or emerge in the context of Brooke–Spiegler syndrome (BSS), an inheritable condition
characterized by mutation of the gene CYLD, encoding a tumour suppressor protein that controls the activity
of the transcription factor NF-kB. Sporadic cylindromas present histological features shared with adenoid cystic
carcinoma (ACC), a head and neck cancer originating from salivary or other exocrine glands. Like ACCs, sporadic
cylindromas express, although at lower frequency, the aberrant fusion transcript MYB–NFIB. In a paper recently
published in the Journal of Pathology, the research teams led by Neil Rajan and Goran Stenman demonstrate that
CYLD-defective cyclindromas in BSS patients are negative for the MYB–NFIB fusion. Only the wild-type MYB
oncoprotein is activated in the majority of these tumours. RNA interference studies in cells derived from BSS
patients indicate that ablating MYB expression results in a striking reduction of cylindroma cell proliferation,
suggesting that MYB plays a pivotal role in the biology of this cancer. The take-home message of the study is that
activation of MYB, in its wild-type form or fusion derivatives, is a common feature of spontaneous and hereditary
cylindromas, constituting a potentially actionable therapeutic target.
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Familial cylindromatosis, also defined as Brooke–
Spiegler syndrome (BSS), is associated with mutation
of the tumour suppressor gene CYLD [1]. Malignant
transformation of cylindromas is rare, but often results
in the development of high-grade metastatic tumours
that drastically reduce patient survival. The treatment
for these neoplasms is limited to broad margin excision
or high-dose radiotherapy for unresectable tumours. A
deeper understanding of the pathophysiology of cylin-
dromas is essential if new useful therapeutic targets are
to be identified.
It has been suggested that the loss of heterozygosity
in the CYLD locus accounts for the majority of both
familiar and sporadic cylindromas, but the molecular
pathways deregulated in these tumours are still poorly
characterized [1,2]. Histological and morphological
similarities with adenoid cystic carcinomas (ACCs)
led to the hypothesis that the two cancer types might
harbour common molecular alterations. Indeed, a frac-
tion of sporadic cylindromas and approximately half of
ACCs express the MYB–NFIB fusion gene [3]. c-MYB
(hereafter indicated by MYB) is a transcription factor
encoded by a gene belonging to a small family that
also includes MYBL2 (encoding B-MYB) and MYBL1
(encoding A-MYB). They share a DNA binding domain
that recognizes the consensus sequence C/TAACNG,
frequently observed in the enhancers of genes asso-
ciated with cell cycle progression, regulation of cell
survival and lineage specification [4]. It is likely that
spatio-temporal distribution, more than structural differ-
ences, explains the requirement of the different MYBs
in organism and tissue development. There is a growing
body of evidence suggesting that MYB proteins play an
important role in human cancer, with different family
members mutated or activated in leukaemia, neurob-
lastoma, brain, colon, liver and breast cancers [5–8].
The majority of ACCs display rearrangements of the
MYB locus, with recurrent fusions of MYB with the
transcription factor NFIB [9]. More recently, it has been
shown that MYB–NFIB fusion-negative, but MYB locus
rearranged, ACCs display activation of MYB caused
by the translocation of super-enhancers near the gene
[10]. Thus, activation of MYB might explain the similar
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Figure 1. Different modalities of MYB activation in familial and sporadic cylindromas: (left panel) in normal epidermal cells the tumour
suppressor gene CYLD inhibits NF-kB, HDACs and possibly additional molecules and pathways (indicated by the question marks); (centre
panel) mutations of CYLD in familial cylindromas disrupt the block on NF-kB, HDACs and/or other molecular pathways, leading to the
activation of MYB (green arrows) and the anti-apoptotic proteins Bcl2 and Birc3; (right panel) in sporadic cylindromas and ACCs the t(6:9)
or other translocations involving the MYB locus activate expression of the MYB oncoprotein via the formation of fusion genes or epigenetic
rearrangements
In a study recently published in the Journal of
Pathology, Rajan et al [11] investigated the role of
MYB in CYLD-defective cylindromas and spyroadeno-
mas. The same group previously observed a relatively
high incidence of MYB–NFIB fusion transcripts in
sporadic cylindromas [3]. Surprisingly, when the
researchers analysed a cohort of samples deriving from
CYLD-defective familial tumours, they did not detect
MYB–NFIB fusion transcripts or rearrangements of the
MYB locus. However, immunohistochemical analysis
revealed strong nuclear expression of MYB in the
majority of BSS tumours. Importantly, they verified
that the expression of the oncoprotein is significantly
higher in cancer than in normal skin. To verify the
functional significance of MYB activation in cylindro-
mas, the research team implemented RNA interference
experiments in which they depleted the expression of
MYB in primary tumour cultures derived from patients.
Reduced MYB expression caused a significant decrease
in tumour cell proliferation. These findings confirm
that overexpression of MYB is a key feature of famil-
ial cylindromas and link the mutation of the tumour
suppressor gene CYLD with MYB activation. Heterozy-
gosity of the CYLD locus has been observed in a fraction
of sporadic cases of cylindroma [12]. Since MYB–NFIB
fusions are also observed in these tumours, it would
be interesting to assess whether these chromosomal
rearrangements are mutually exclusive with CYLD
alterations. This would corroborate the hypothesis that
increased expression of MYB, either as MYB–NFIB
fusion or wild-type protein, is the causative event in
these tumours.
CYLD is a de-ubiquitylating enzyme that regu-
lates protein stability by removing poly-ubiquitin
chains from substrates. CYLD loss has been shown
to promote survival or proliferation of different cell
types, supporting the hypothesis that it may act as a
tumour suppressor. Prior to the study by Rajan et al
[11], there was no evidence of a link between MYB
and CYLD pathways in cancer cells. The authors of
the study suggest that a possible explanation for the
activation of MYB in CYLD mutant cells may rest in
the loss of control of NF-kB activity. Indeed, CYLD
inactivation causes increased NF-kB signalling and it
was previously reported that the MYB promoter con-
tains NF-kB binding sites, transactivated by NF-kB
[13,14]. Perplexingly, however, Rajan et al [11] did not
observe perturbation of MYB expression after drugging
NF-kB in cylindroma cells, suggesting that another
circuitry linking CYLD and MYB must be operating
in cutaneous tumours. It is tempting to speculate that
CYLD could alter chromatin dynamics in the MYB
locus, since recent studies have revealed that CYLD
negatively controls the activity of histone deacetylases
HDAC6 and HDAC7 in mammalian cells [15,16].
Intriguingly, the pan-HDAC inhibitor Givinostat has
been shown to strongly down-regulate MYB expression
in leukaemic cells, indicating that histone acetylation
changes might be crucially linked to MYB activation
in cancer. This hypothesis is corroborated by a study
demonstrating epigenetic activation of the MYB locus
in MYB–NFIB-negative, but translocation-positive,
ACCs [10]. Taken together, these studies strongly indi-
cate that the pathogenic cause of cylindromas and ACCs
is the activation of MYB.
Of course, there are still important questions awaiting
an answer: is MYB necessary and sufficient for the trans-
formation of cutaneous and glandular cells? What are
the critical MYB target genes? To start answering the lat-
ter question, Rajan et al [11] conducted gene expression
analyses on previously published microarray datasets.
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MYB is frequently overexpressed in familial dermal cylindromas 3
involved in the control of apoptosis, BCL2 and BIRC3,
which were significantly up-regulated in cylindromas
compared to normal skin. Satisfyingly, ablation of MYB
reduced the expression of BCL2 and BIRC3 in cylin-
droma cells, suggesting that MYB also precipitates cuta-
neous tumourigenesis through inhibition of apoptosis.
Whether or not MYB is the key driver of cyclindroma,
or other head and neck cancers, will only be estab-
lished by developing appropriate transgenic models or
by implementing DNA-editing strategies that reproduce
the genomic rearrangements leading to MYB activation.
These findings of Rajan et al [11] give hope to patients
affected by malignant cylindroma. Small-molecule
inhibitors of MYB are being developed, some of which
show promise in preclinical experiments. For example,
the multi-kinase inhibitor Rigosertib induces selective
killing of diffuse large B cell lymphoma by suppressing
TRAF6 and MYB [17]. Interestingly, TRAF6 is an
adaptor protein involved in tumour development and
was previously shown to be a CYLD target protein
[18]. It will be important to assess whether Rigosertib
kills or reduces the proliferation of cylindroma cells in
preclinical experiments.
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